Weber, J. S., Haque, W., Markovic, S. N., Salama, A. K. S., Mehmi, I., Sullivan, R. J., … Norton, D. (2023). 1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma. In Annals of Oncology (Vol. 34, pp. S657–S658). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2225

Weber, J. S., W. Haque, S. N. Markovic, A. K. S. Salama, I. Mehmi, R. J. Sullivan, Y. G. Najjar, et al. “1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma.” In Annals of Oncology, 34:S657–58. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2225.

Weber JS, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, et al. 1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma. In: Annals of Oncology. Elsevier BV; 2023. p. S657–8.

Weber, J. S., et al. “1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S657–58. Crossref, doi:10.1016/j.annonc.2023.09.2225.

Weber JS, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen JBAG, Zijlker L, Davis K, Karanth S, Shah R, Connolly L, Norton D. 1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma. Annals of Oncology. Elsevier BV; 2023. p. S657–S658.